

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 3705

DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE,
FOOD AND DRUG ADMINISTRATION,
Washington, D.C., October 23, 1967.

"Vibramycin Suspension"—NDA 50-006

"Vibramycin Capsules"—NDA 50-007

Re Vibramycin—148z.3 and 148z.4.

CHAS. PFIZER & Co., INC.,

New York, N.Y.

(Attention: Mr. M. G. Adair)

GENTLEMEN: We have no objection to the Vibramycin visual aid (P159x67R1—Issued October 1967) submitted with your letter of October 6, 1967, nor to the manner in which you propose to dispose of copies of the previous visual aid and compendium.

The draft of the compendium submitted with your letter of October 2, 1967 is satisfactory.

Sincerely yours,

B. H. MINCHEW,
HERBERT L. LEY, Jr., M.D.,
Director, Bureau of Medicine.

Senator NELSON. I want to thank you very much for your presentation this morning. Our next hearing will be on Wednesday at 10 a.m. The witness will be Dr. Philip Lee, Assistant Secretary of HEW, and staff, to discuss the HEW Task Force Report on Prescription Drugs.

Thank you very much.

(Whereupon, at 10:45 a.m., the committee adjourned until Wednesday, September 25, 1968, at 10 a.m.)